DRTX (MM)

Durata Therapeutics (Nasdaq:DRTX) today announced the company will participate in the RBC Capital Markets' Global Healthcare Conference scheduled for February 26 and 27, 2013 at The Plaza Hotel in New York City. Durata's Chief Executive Officer Paul R. Edick will participate in a fireside chat on Tuesday, February 26, 2013 at 11 a.m. ET. The fireside chat will be webcast and will be available live and archived for 30 days at http://www.veracast.com/webcasts/rbc/healthcare2013/23107333.cfm as well on the Investor Relations section of the Company's website at www.duratatherapeutics.com.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed its DISCOVER 1 study and enrollment in its DISCOVER 2 global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.

The Durata Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16463

Forward-looking statements

Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.

CONTACT: Investor Relations and Public Affairs Contact
         Allison Wey - Durata Therapeutics
         Vice President, Investor Relations and Public Affairs
         (312)219-7017 - awey@duratatherapeutics.com